Literature DB >> 17355857

Electrically assisted ocular gene therapy.

Riad Antoine Bejjani1, Charlotte Andrieu, Carole Bloquel, Marianne Berdugo, David BenEzra, Francine Behar-Cohen.   

Abstract

Electrotransfer and iontophoresis are being developed as innovative non-viral gene delivery systems for the treatment of eye diseases. These two techniques rely on the use of electric current to allow for higher transfection yield of various ocular cell types in vivo. Short pulses of relatively high-intensity electric fields are used for electrotransfer delivery, whereas the iontophoresis technique is based on the application of low voltage electric current. The basic principles of these techniques and their potential therapeutic application for diseases of the anterior and posterior segments of the eye are reviewed. Iontophoresis has been found most efficient for the delivery of small nucleic acid fragments such as antisense oligonucleotides, siRNA, or ribozymes. Electrotransfer, on the other hand, is being developed for the delivery of oligonucleotides or custom designed plasmids. The wide range of strategies already validated and the potential for targeting specific types of cells confirm the promising early observations made using electrotransfer and iontophoresis. These two nonviral delivery systems are safe and can be used efficiently for targeted gene delivery to ocular tissues in vivo. At the present, their application for the treatment of ocular human diseases is nearing its final stages of adaptation and practical implementation at the bedside.

Entities:  

Mesh:

Year:  2007        PMID: 17355857     DOI: 10.1016/j.survophthal.2006.12.005

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  8 in total

1.  Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina.

Authors:  Elodie Touchard; Marianne Berdugo; Pascal Bigey; Mohamed El Sanharawi; Michèle Savoldelli; Marie-Christine Naud; Jean-Claude Jeanny; Francine Behar-Cohen
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

2.  Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

Authors:  Henry F Edelhauser; Cheryl L Rowe-Rendleman; Michael R Robinson; Daniel G Dawson; Gerald J Chader; Hans E Grossniklaus; Kay D Rittenhouse; Clive G Wilson; David A Weber; Baruch D Kuppermann; Karl G Csaky; Timothy W Olsen; Uday B Kompella; V Michael Holers; Gregory S Hageman; Brian C Gilger; Peter A Campochiaro; Scott M Whitcup; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-11       Impact factor: 4.799

Review 3.  [Gene therapy as a treatment concept for inherited retinal diseases].

Authors:  J-S Bellingrath; M D Fischer
Journal:  Ophthalmologe       Date:  2015-09       Impact factor: 1.059

Review 4.  Gene delivery to cornea.

Authors:  Jinsong Hao; S Kevin Li; Winston W Y Kao; Chia-Yang Liu
Journal:  Brain Res Bull       Date:  2009-06-26       Impact factor: 4.077

Review 5.  Ocular Barriers and Their Influence on Gene Therapy Products Delivery.

Authors:  Bastien Leclercq; Dan Mejlachowicz; Francine Behar-Cohen
Journal:  Pharmaceutics       Date:  2022-05-06       Impact factor: 6.525

6.  In vitro extraction of intra-corneal iron using reverse iontophoresis and vitamin C.

Authors:  Jian-Hai Bai; Sheng Su; Lei Huang; Yan-Yan Zhang; Yun-Song Wang; Mei-Hua Guo; Hong-Bin Yang; Hao Cui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-06-05       Impact factor: 3.117

7.  Electrically assisted delivery of macromolecules into the corneal epithelium.

Authors:  Jinsong Hao; S Kevin Li; Chia-Yang Liu; Winston W Y Kao
Journal:  Exp Eye Res       Date:  2009-08-12       Impact factor: 3.467

Review 8.  Delivery systems and local administration routes for therapeutic siRNA.

Authors:  Fabiana Testa Moura de Carvalho Vicentini; Lívia Neves Borgheti-Cardoso; Lívia Vieira Depieri; Danielle de Macedo Mano; Thais Fedatto Abelha; Raquel Petrilli; Maria Vitória Lopes Badra Bentley
Journal:  Pharm Res       Date:  2013-01-24       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.